Eficacia comparada del tiocolchicosido en el manejo del dolor agudo secundario a espasmo muscular
Autor: Dr. Germán Cisneros | Publicado:  27/07/2011 | Anestesiologia y Reanimacion , Farmacologia , Traumatologia , Articulos | |
Eficacia comparada del tiocolchicosido en el manejo dolor agudo secundario a espasmo muscular .3

BIBLIOGRAFÍA

1. Cohen SP, Mullings R, Abdi S. The pharmacologic treatment of muscle pain. Anesthesiology 2004 Aug; 101 (2): 495-526
2. Tüzün F, Ünalan H, Öner N, Özgüzel H, Kirazli Y, Icagasioglu A, Banu K, Tüzün S, Basar G. Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain. Join Bone Spine 2003 Sep; 70 (5): 356-361
3. Aksoy C, Karan A, Diracoglu D. Low back pain: results of an open clinical trial comparing the standard treatment alone to the combination of standard treatment and thiocolchicoside. J Orthopaed Traumatol 2002; 3 (2): 103-108
4. Koes BW, van Tulder MW, Ostelo R, Kim Burton A, Waddell G. Clinical guidelines for the management of low back pain in primary care: an international comparison. Spine 2001 Nov; 26 (22): 2504 - 2514
5. Borenstein DG. Epidemiology, etiology, diagnostic evaluation and treatment of low back pain. Curr Opin Rheumatol 2001 Mar; 13 (2): 128-134
6. Van Tulder MM, Scholten RJ, Koes BW, Deyo RA. Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review with the framework of the Cochrane Collaboration Back Review Group. Spine 2000 Oct; 25 (19): 2501-2513
7. Trellu M, Filali-Ansari A, Francon D, Adam R, Lluel P, Dubruc C, Thénot JP. New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. Fundam Clin Pharmacol. 2004; (18): 493 - 501
8. Ketenci A, Ozcan E, Karamursel S. Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain. Int J Clin Pract, 2005 Jul: 59 (7): 764–770
9. Peloso PMJ, Gross A, Haines T, Cervical Overview Group. Medicinal and inyection therapies for mechanical neck disorders. Cochrane Datbase of Systematic Reviews 2007. Issue 3. Art. No CD 000 319.
10. Soonawalla DF, Joshi N. Efficacy of thiocolchicoside in Indian patients suffering from low back pain associate with muscle spasm. J Indian Med Assoc. 2008 May; 106 (5): 331-335.
11. Ketenci A, Basat H, Esmaeilzadeh S. The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain sindrome: a single-blend, randomized, prospective, phase IV clinical study. Agri. 2009 Jul; 21 (3): 95-103.
12. Carta M, Murru L, Botta P, Talan G, Sechi G, De Riu P, Sanna E, Bigglo G. The muscle relaxant thiocolchicoside is an antagonist of GABA A receptor function in the central nervous system. Neuropharmacology 2006 Sep; 51 (4): 805-15
13. De Riu PL, Rosati G, Satgiu S, Sechi G. Epileptic seizures alter treatment with thiocolchicoside. Epilepsia 2001 Aug; 42 (8): 1084-6
14. Giavina-Bianchi P, Giavina-Bianchi M, Tannu LK, Ensina LF, Motta AA, Kali L. Epileptic seizure alter treatment with thiocolchicoside . Ther Clin Risk Manag. 2009 Jun; 5 (3): 635-7.
15. Ferrari MP, Gatti G, Falttore C, Fedele G, Novellini R. Comparative bioavailability and tolerability atudy of two intramuscular formulations of thiocolchicoside in healthy volunteers. Eur J Drug Metab Pharmacokinet 2001 Oct-Dec; 26 (4): 257-62
16. Anaracdio R, Perilla O, Pagnanelli F, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibiity betwen thiocolchicoside injections (Miotens) and pharmaceuticals products frequently used for combined therapy. Fármaco 2002 Nov; 57 (11): 925-30
17. Guarneri C, Polimeni G, Guarneri F, Cuzzocrea S. Embolia cutis medicamentosa following thiocolchicoside injection. J Eur Acad Dermatol Venereol 2008 Aug; 22 (8): 1005-6
18. Guarneri F, Guarneri C, Cannavo SP. Skin atrophy caused by thiocolchicoside ijections. Int J Dermatol 2006 Dec; 45 (12): 1473-4.
19. http://www.facmed.unam.mx/bmnd/plm_2k8src/prods/34188.htm
20. http://www.minsa.gob.pe/portalbiblioteca2/biblio/plm/PLM/productos/52359.htm

DECLARACIÓN DE CONFLICTO DE INTERESES

Los autores no tienen relación de dependencia ni han recibido subvención alguna por el presente estudio, de parte de alguna institución o de los productores de los medicamentos utilizados. Tiocolchicósido (TCC) fue suministrado por SANOFI-AVENTIS y se usó KETOROLACO genérico Magma. Los gastos operativos fueron asumidos por los autores.


Revista Electronica de PortalesMedicos.com
INICIO - NOVEDADES - ÚLTIMO NÚMERO - ESPECIALIDADES - INFORMACIÓN AUTORES
© PortalesMedicos, S.L.
PortadaAcerca deAviso LegalPolítica de PrivacidadCookiesPublicidadContactar